Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis

Autor: Paller, AS, Ladizinski, B, Mendes-Bastos, P, Siegfried, E, Soong, W, Prajapati, VH, Lio, P, Thyssen, JP, Simpson, EL, Platt, AM, Raymundo, EM, Liu, J, Calimlim, BM, Huang, X, Gu, Y, Hu, X, Yang, Y, Su, JC, Zheng, M, Yamamoto-Hanada, K, Teixeira, HD, Irvine, AD

Importance: Atopic dermatitis onset usually occurs in childhood. Persistence of disease into adolescence and adulthood is common. It is important to evaluate new treatment options in adolescents because of the high unmet need in this population. Obje

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1714::4805f96850a61bbc6c3a628c24d25e19
https://hdl.handle.net/10400.26/44841

Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1).

Autor: King B; Department of Dermatology, Yale School of Medicine, New Haven, Connecticut. Electronic address: brett.king@yale.edu., Senna MM; Department of Dermatology, Lahey Hair Loss Center of Excellence, Lahey Hospital and Medical Center, Burlington, Massachusetts., Mesinkovska NA; Department of Dermatology, University of California, Irvine, California., Lynde C; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Lynderm Research Inc., Probity Medical Research, Markham, Ontario, Canada., Zirwas M; DOCS Dermatology, Columbus, Ohio., Maari C; Faculty of Medicine, Department of Medicine, University of Montreal, Montreal, Quebec, Canada., Prajapati VH; Division of Dermatology, Department of Medicine, and Sections of Community Pediatrics and Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada; Dermatology Research Institute, Probity Medical Research, Skin Health & Wellness Centre, Calgary, Alberta, Canada., Sapra S; Institute of Cosmetic and Laser Surgery, Oakville, Ontario, Canada., Brzewski P; Department of Dermatology, Jagiellonian University, Krakow, Poland., Osman L; Quest Dermatology Research, Northridge, California., Hanna S; Department of Medicine, Division of Dermatology, University of Toronto, Toronto, Ontario, Canada; Dermatology On Bloor, Toronto, Ontario, Canada., Wiseman MC; Section of Dermatology, Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada., Hamilton C; Sun Pharmaceutical Industries, Inc., Lexington, Massachusetts., Cassella J; Sun Pharmaceutical Industries, Inc., Lexington, Massachusetts.

Publikováno v: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Nov; Vol. 91 (5), pp. 880-888. Date of Electronic Publication: 2024 Jul 23.

Effectiveness and Safety of Upadacitinib in Adolescent and Adult Patients with Atopic Dermatitis: An Analysis of Long-Term (Week 52) Data from a Real-World Multicenter Retrospective Review.

Autor: Rankin BD; Department of Medicine, Division of Dermatology, University of Calgary, Calgary, Canada., Sood S; Temerty Faculty of Medicine, University of Toronto, Toronto, Canada., Park YJ; Temerty Faculty of Medicine, University of Toronto, Toronto, Canada., Rimke A; Dermatology Research Institute, Calgary, Canada., Abduelmula A; Department of Medicine, Division of Dermatology, University of Toronto, Toronto, Canada., Georgakopoulos JR; Department of Medicine, Division of Dermatology, University of Toronto, Toronto, Canada., Maliyar K; Department of Medicine, Division of Dermatology, University of Toronto, Toronto, Canada., Leung F; Dermatology Research Institute, Calgary, Canada.; Skin Health & Wellness Centre, Calgary, Canada., Stark LA; Dermatology Research Institute, Calgary, Canada.; Skin Health & Wellness Centre, Calgary, Canada., Devani AR; Dermatology Research Institute, Calgary, Canada.; Skin Health & Wellness Centre, Calgary, Canada.; Probity Medical Research, Waterloo, Canada., Yeung J; Department of Medicine, Division of Dermatology, University of Toronto, Toronto, Canada.; Probity Medical Research, Waterloo, Canada.; Department of Medicine, Division of Dermatology, Women's College Hospital, Toronto, Canada.; Department of Medicine, Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Canada., Prajapati VH; Department of Medicine, Division of Dermatology, University of Calgary, Calgary, Canada.; Dermatology Research Institute, Calgary, Canada.; Skin Health & Wellness Centre, Calgary, Canada.; Probity Medical Research, Waterloo, Canada.; Section of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, Canada.; Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Canada.

Publikováno v: Dermatitis : contact, atopic, occupational, drug [Dermatitis] 2024 Oct 24. Date of Electronic Publication: 2024 Oct 24.

Effectiveness and safety of risankizumab dose optimization in adult patients with plaque psoriasis: An international multicentre retrospective cohort study.

Autor: Bagit A; Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada., Maliyar K; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Mansour M; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Georgakopoulos JR; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Rankin B; Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada., Lytvyn Y; Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Zaaroura H; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Park YJ; Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada., Wang E; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Mufti A; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.; Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Torres T; Department of Dermatology, Centro Hospitalar de Santo António, Porto, Portugal.; Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal., Le AM; Department of Dermatology, Centro Hospitalar de Santo António, Porto, Portugal., Vender R; Dermatrials Research Inc. and Venderm Consulting, Hamilton, Ontario, Canada., Prajapati VH; Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.; Dermatology Research Institute, Calgary, Alberta, Canada.; Probity Medical Research, Calgary, Alberta, Canada.; Skin Health & Wellness Centre, Calgary, Alberta, Canada.; Section of Community Pediatrics, University of Calgary, Calgary, Alberta, Canada.; Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada., Yeung J; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.; Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.; Division of Dermatology, Women's College Hospital, Toronto, Ontario, Canada.; Probity Medical Research, Toronto, Ontario, Canada.

Publikováno v: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2024 Oct 15. Date of Electronic Publication: 2024 Oct 15.

Systemic Janus kinase inhibitor treatment for vitiligo: An evidence-based review.

Autor: Sood S; Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada., Varenbut J; Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada., Bagit A; Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada., Perlmutter J; Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada., Maliyar K; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Sachdeva M; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Abduelmula A; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Georgakopoulos JR; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Mufti A; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Prajapati VH; Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; Dermatology Research Institute, Calgary, Alberta, Canada; Skin Health & Wellness Centre, Calgary, Alberta, Canada; Section of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada; Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada; Probity Medical Research, Waterloo, Ontario, Canada., Yeung J; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Probity Medical Research, Waterloo, Ontario, Canada; Department of Dermatology, Women's College Hospital, Toronto, Ontario, Canada. Electronic address: jensen.yeung@utoronto.ca.

Publikováno v: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Sep 16. Date of Electronic Publication: 2024 Sep 16.